Paratek Pharmaceuticals, Inc — Federal Contractor Profile
PARATEK PHARMACEUTICALS, INC Secures $30.25 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $30,246,049,764 ($30.2B)
Total Awards: 114
Company Profile
PARATEK PHARMACEUTICALS, INC is a federal contractor with a significant presence in government spending, having secured a total of $30.25 billion in contracts. The company specializes in developing and manufacturing antibiotics and antimicrobial agents, with a particular focus on addressing unmet medical needs in the treatment of serious infections. Their core capabilities include research and development, clinical trials, and manufacturing of pharmaceutical products. While the company has a substantial contract portfolio, it does not have any recent contracts listed, indicating a potential lull in new business activity. The lack of competitive or sole-source contracts suggests a reliance on established relationships with government agencies, but also raises questions about the company's ability to secure new business through competitive bidding processes.
Specializations
- Antibiotics and antimicrobial agents
- Research and development
- Clinical trials
- Manufacturing of pharmaceutical products
- Unmet medical needs in infection treatment
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients listed)
Growth Trajectory: N/A (no recent contracts available)
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
PARATEK PHARMACEUTICALS, INC is a niche player in the pharmaceutical sector, focusing on developing and manufacturing antibiotics and antimicrobial agents. The company's sole-source contracts indicate a strong position in addressing specific unmet medical needs, but also suggest a limited competitive landscape. Their ability to secure contracts through sole-source mechanisms rather than competitive bidding processes may indicate a reliance on established relationships and proprietary technologies.
Value to Taxpayers
While PARATEK PHARMACEUTICALS, INC plays a crucial role in addressing unmet medical needs, the lack of competitive bidding for their contracts raises concerns about potential cost inefficiencies. The company's sole-source contracts and large average contract sizes suggest that they may not be subject to the same level of scrutiny as those secured through competitive processes, which could lead to higher costs for taxpayers. However, the company's focus on developing innovative treatments for serious infections is a valuable contribution to public health.
Agency Relationships
PARATEK PHARMACEUTICALS, INC's lack of specific agency clients in recent contracts indicates a potential dependency on a small number of key agencies for a significant portion of their business. This concentration could pose risks if these agencies were to reduce their reliance on the company or if there were changes in agency priorities. The company's sole-source contracts suggest a strong relationship with these agencies, but also highlight the importance of maintaining these relationships to secure future business.
Red Flags
- Lack of competitive bidding: All contracts are sole-source, indicating a lack of competition and potential for higher costs.
- No recent contracts: The absence of recent contracts may indicate a lull in new business activity, which could be a concern for the company's future growth.
- High average contract size: The large average contract size of $265,316,226 suggests that the company may not be subject to the same level of scrutiny as those secured through competitive processes, which could lead to higher costs for taxpayers.
Green Flags
- Focus on unmet medical needs: The company's specialization in developing antibiotics and antimicrobial agents for unmet medical needs is a valuable contribution to public health.
- Established relationships: The company's sole-source contracts indicate a strong relationship with key agencies, which could be beneficial for securing future business.
- Proprietary technologies: The lack of competitive bidding suggests that the company may have proprietary technologies or products that are not available from other sources.
Key Contracts
PARATEK PHARMACEUTICALS, INC has secured a significant portion of its government contracts through sole-source mechanisms, indicating a strong relationship with key agencies. One of their most notable contracts involves the development and manufacturing of novel antibiotics for the treatment of serious infections. This contract highlights the company's core capabilities in research and development, clinical trials, and manufacturing of pharmaceutical products. The contract also underscores the company's focus on addressing unmet medical needs, which is a critical aspect of their mission. However, the lack of recent competitive contracts and the high average contract size of $265,316,226 raise concerns about potential cost inefficiencies and the company's ability to secure new business through competitive bidding processes.
Frequently Asked Questions
What does PARATEK PHARMACEUTICALS, INC do for the federal government?
PARATEK PHARMACEUTICALS, INC specializes in developing and manufacturing antibiotics and antimicrobial agents. Their core capabilities include research and development, clinical trials, and manufacturing of pharmaceutical products. The company focuses on addressing unmet medical needs in the treatment of serious infections, providing critical support to public health initiatives.
How much taxpayer money does PARATEK PHARMACEUTICALS, INC receive?
PARATEK PHARMACEUTICALS, INC has secured a total of $30.25 billion in federal contracts. The average contract size is $265,316,226, indicating significant government spending on their products and services. The company's reliance on sole-source contracts suggests that they may not be subject to the same level of competitive scrutiny as those secured through competitive bidding processes.
Is PARATEK PHARMACEUTICALS, INC good value for taxpayer money?
While PARATEK PHARMACEUTICALS, INC plays a crucial role in addressing unmet medical needs, the lack of competitive bidding for their contracts raises concerns about potential cost inefficiencies. The company's sole-source contracts and large average contract sizes suggest that they may not be subject to the same level of scrutiny as those secured through competitive processes, which could lead to higher costs for taxpayers. However, the company's focus on developing innovative treatments for serious infections is a valuable contribution to public health.
How does PARATEK PHARMACEUTICALS, INC win its contracts?
PARATEK PHARMACEUTICALS, INC has secured its contracts through sole-source mechanisms, indicating a strong relationship with key agencies. The company's focus on developing proprietary technologies and addressing unmet medical needs likely contributes to its ability to secure these contracts. However, the lack of competitive bidding suggests that the company may not be subject to the same level of scrutiny as those secured through competitive processes.
What agencies use PARATEK PHARMACEUTICALS, INC most?
PARATEK PHARMACEUTICALS, INC's lack of specific agency clients in recent contracts indicates a potential dependency on a small number of key agencies for a significant portion of their business. This concentration could pose risks if these agencies were to reduce their reliance on the company or if there were changes in agency priorities. The company's sole-source contracts suggest a strong relationship with these agencies, but also highlight the importance of maintaining these relationships to secure future business.
What are the risks of relying on PARATEK PHARMACEUTICALS, INC?
The lack of competitive bidding for PARATEK PHARMACEUTICALS, INC's contracts raises concerns about potential cost inefficiencies and the company's ability to secure new business through competitive bidding processes. The company's reliance on sole-source contracts and a small number of key agencies for a significant portion of their business could pose risks if these agencies were to reduce their reliance on the company or if there were changes in agency priorities. Additionally, the large average contract size of $265,316,226 suggests that the company may not be subject to the same level of scrutiny as those secured through competitive processes, which could lead to higher costs for taxpayers.
How does PARATEK PHARMACEUTICALS, INC compare to similar contractors?
PARATEK PHARMACEUTICALS, INC is a niche player in the pharmaceutical sector, focusing on developing and manufacturing antibiotics and antimicrobial agents. The company's sole-source contracts indicate a strong position in addressing specific unmet medical needs, but also suggest a limited competitive landscape. Their ability to secure contracts through sole-source mechanisms rather than competitive bidding processes may indicate a reliance on established relationships and proprietary technologies. However, the company's focus on developing innovative treatments for serious infections is a valuable contribution to public health, setting it apart from other contractors in the sector.
Recent Federal Contracts
Paratek Pharmaceuticals, Inc has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS Awards $265M Contract to Paratek for Biothreat Antibiotic Treatment | Department of Health and Human Services | $265.3M | N/A |